Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Breast Neoplasms 8Neoplasms 4Multiple Myeloma 3Radiation Injuries 2Multiple Chronic Conditions 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Esophageal Neoplasms 2Cognitive Dysfunction 2Brain Neoplasms 2Substance-Related Disorders 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pain 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mobility Limitation 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Hyperthermia 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 220Rituximab 189fludarabine phosphate 169fludarabine 102Peripheral Blood Stem Cell Transplantation 100Mycophenolic Acid 94Whole-Body Irradiation 81Tacrolimus 72Filgrastim 69Cyclosporine 67Lenalidomide 66ibrutinib 63Busulfan 61Melphalan 58Antilymphocyte Serum 57Radiotherapy 52venetoclax 48Etoposide 47obinutuzumab 42Bendamustine Hydrochloride 42Alemtuzumab 41Methotrexate 39ofatumumab 28sargramostim 27Granulocyte Colony-Stimulating Factor 26Cytarabine 26Cord Blood Stem Cell Transplantation 26acalabrutinib 25Stem Cell Transplantation 24Specimen Handling 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphocytic, Chronic, B-Cell × Patient Reported Outcome Measures × Clear all
NCT04663100 2023-12-04

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

University of Tennessee

Phase NA Unknown
30 enrolled
LymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cell

Multiple Chronic Conditions, Leukemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT04595851 2022-11-22

Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

University of Michigan Rogel Cancer Center

Phase NA Terminated
6 enrolled
LymphoidMyeloidOther hematologic neoplasmOther neoplasm

Multiple Chronic Conditions, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡